Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | The future of CTCL therapy

Martine Bagot • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Antibodies

Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, suggests how the therapeutic landscape of cutaneous T-cell lymphoma (CTCL) may evolve in the future, with the development of novel monoclonal antibodies, oncogenic peptides, and agents targeting overactivated signaling pathways in CTCL. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Martine Bagot

1:05
Updates on the TELLOMAK trial
Martine Bagot • 15 Oct 2021
0:40
MAVORIC: long-term clinical benefit of mogamulizumab in patients with CTCL
Martine Bagot • 15 Oct 2021
0:54
Mogamulizumab-associated rash in CTCL
Martine Bagot • 15 Oct 2021
0:37
EORTC CL highlights: in-person discussions and collaborations
Martine Bagot • 15 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals